Hudson Bay Capital Management LP Reduces Position in Alnylam Pharmaceuticals, Inc. $ALNY

Hudson Bay Capital Management LP decreased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 38.7% during the 3rd quarter, HoldingsChannel reports. The fund owned 9,411 shares of the biopharmaceutical company’s stock after selling 5,937 shares during the quarter. Hudson Bay Capital Management LP’s holdings in Alnylam Pharmaceuticals were worth $4,291,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ALNY. OFI Invest Asset Management grew its stake in Alnylam Pharmaceuticals by 5.8% during the 3rd quarter. OFI Invest Asset Management now owns 403 shares of the biopharmaceutical company’s stock valued at $184,000 after purchasing an additional 22 shares in the last quarter. Howard Capital Management Inc. raised its position in shares of Alnylam Pharmaceuticals by 2.9% in the 3rd quarter. Howard Capital Management Inc. now owns 854 shares of the biopharmaceutical company’s stock valued at $389,000 after purchasing an additional 24 shares in the last quarter. Frank Rimerman Advisors LLC boosted its stake in shares of Alnylam Pharmaceuticals by 2.0% during the 3rd quarter. Frank Rimerman Advisors LLC now owns 1,251 shares of the biopharmaceutical company’s stock valued at $570,000 after buying an additional 24 shares during the last quarter. Coastal Bridge Advisors LLC grew its position in shares of Alnylam Pharmaceuticals by 2.3% during the third quarter. Coastal Bridge Advisors LLC now owns 1,097 shares of the biopharmaceutical company’s stock worth $500,000 after buying an additional 25 shares in the last quarter. Finally, Meridian Financial Advisors LLC grew its position in shares of Alnylam Pharmaceuticals by 3.5% during the third quarter. Meridian Financial Advisors LLC now owns 828 shares of the biopharmaceutical company’s stock worth $378,000 after buying an additional 28 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Up 0.3%

Shares of Alnylam Pharmaceuticals stock opened at $312.17 on Friday. The stock has a market capitalization of $41.40 billion, a price-to-earnings ratio of 182.56 and a beta of 0.36. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $495.55. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28. The business’s 50 day simple moving average is $335.41 and its 200-day simple moving average is $405.07.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $1.25 EPS for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.18). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The company had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $1.16 billion. During the same quarter in the previous year, the company earned ($0.65) earnings per share. Alnylam Pharmaceuticals’s quarterly revenue was up 84.9% compared to the same quarter last year. Equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Analysts Set New Price Targets

ALNY has been the topic of several recent analyst reports. Canaccord Genuity Group upped their price target on shares of Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. Raymond James Financial reissued an “outperform” rating and issued a $472.00 target price on shares of Alnylam Pharmaceuticals in a research report on Monday, January 12th. Bank of America restated a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 12th. Needham & Company LLC reduced their price target on shares of Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating on the stock in a research report on Thursday, February 12th. Finally, Weiss Ratings upgraded Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Thursday, January 15th. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $468.84.

Insider Activity

In other news, EVP Pushkal Garg sold 2,242 shares of the company’s stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $310.08, for a total transaction of $695,199.36. Following the completion of the transaction, the executive vice president owned 24,848 shares in the company, valued at approximately $7,704,867.84. This represents a 8.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Yvonne Greenstreet sold 9,577 shares of the stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $362.86, for a total transaction of $3,475,110.22. Following the completion of the sale, the chief executive officer directly owned 78,411 shares in the company, valued at approximately $28,452,215.46. This trade represents a 10.88% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 53,923 shares of company stock worth $18,072,087. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.